Bayer Faces Setbacks as €7.25 Billion Roundup Settlement Raises Questions | Science-Environment
Bayer's stock fell sharply as investor concerns emerged regarding a $7.25 billion settlement for Roundup cancer lawsuits.Summary
Bayer's share value experienced a significant drop of up to 9.2% on Wednesday, reversing previous gains, as investors expressed doubts about a proposed €7.25 billion settlement intended to resolve cancer lawsuits linked to its Roundup weedkiller. This settlement aims to address claims from tens of thousands of current and future plaintiffs, originating from Bayer’s 2018 acquisition of Monsanto. While the stock had seen a 7.3% increase on Tuesday, this was overshadowed by an 8% decline later in the day. JPMorgan analysts recognized the settlement as a positive step but highlighted uncertainties surrounding the number of plaintiffs needed to opt-in and their acceptance of the settlement terms. Further complicating matters are pending legal challenges and a forthcoming decision from the U.S. Supreme Court regarding the fundamental legal aspects of the case, as emphasized by Oddo BHF's Stephan Wulf. Court approval and potential opt-outs also remain critical factors in finalizing the agreement.
(Source：Devdiscourse)